During infection, the pathogenic bacterium interacts closely with the bacteria in the gut. They may have to share resources, thereby limiting infection with the pathogen, or alternatively the pathogen may draw benefits from this cohabitation for its infectious strategy.

As part of her trip to France for the fourth Paris Peace Forum – which includes three round tables on the challenges raised by the COVID-19 pandemic –, Kamala Harris, Vice President of the United States, visited the Institut Pasteur on November 9, 2021. She met several of the Institut Pasteur's scientists and saluted the unprecedented response of the Institut Pasteur's scientific community in tackling the COVID-19 epidemic over the past two years.

En déplacement en France à l’occasion du 4^e Forum de Paris sur la Paix au cours duquel trois tables rondes seront consacrées à la lutte contre la pandémie de Covid-19, Kamala Harris, Vice-Présidente des États-Unis, a visité l’Institut Pasteur le 9 novembre 2021. A cette occasion, elle a rencontré plusieurs chercheurs de l’Institut et a salué la mobilisation sans précédent de la communauté scientifique pasteurienne depuis de 2 ans dans la lutte contre l’épidémie de Covid-19.

"Because we realize that time is running out and the world can come to a standstill... research must advance." This is the message of the Institut Pasteur's communications campaign, launched several weeks ago and which will be on TV screens at the end of the year. This message conveys the vital truth that research should never be slowed down or stopped, regardless of the circumstances, if we are to keep pushing the boundaries of scientific knowledge.

Suite à des premiers résultats encourageants, qui seront prépubliés prochainement, l’Institut Pasteur et SpikImm annoncent le développement de l'anticorps SPKM001.

Paris, le 9 septembre 2021

SPKM001 est un anticorps monoclonal de haute affinité ciblant le « RBD » (domaine de liaison au récepteur) sur la protéine Spike de la souche d’origine du virus SARS-CoV-2 et de ses variants.

Following encouraging initial results, which will be published shortly, the Institut Pasteur and SpikImm announce the development of the antibody SPKM001.

Paris, September 9, 2021

SPKM001 is a high affinity human monoclonal antibody which targets the receptor-binding site (RBD) on the Spike protein of the original SARS-CoV-2 strain and its variants.

Initial preclinical results tend to show that this new therapeutic tool is effective in vitro and in vivo. Clinical trials should be conducted to evaluate its efficacy in humans.

Salmonellosis caused by the Salmonella bacterium is the most common example of foodborne infections, which remain a global public health problem, with over 600 million infections and 400,000 deaths every year. Use of antibiotics during outbreaks entails a risk of resistance. Scientists at the Institut Pasteur have demonstrated that bacteriophages may be used as a prophylactic treatment.

Cap'Carnot est la Rencontre d'été annuelle organisée par l’Association des instituts Carnot pour favoriser les rencontres entre les Carnot¹ et les acteurs de l’innovation. Pour sa deuxième édition, Cap'Carnot aura lieu le mardi 28 septembre 2021 de 17h à 20h à NEWCAP, à Paris 15, et sera l’occasion de fêter les 15 ans d'actions de R&D des Carnot.

Monkeypox is an emerging and neglected infectious disease caused by the Monkeypox virus (MPXV). The disease has a similar clinical presentation to smallpox, with a maculopapular rash (a skin rash characterized by small spots), especially on the palms of the hands and the soles of the feet.

In recent years, the scientific community has realized that different bacterial strains can play very different roles in an environment. The identification of these strains and their genomes is important for both basic research and human health. Scientists from the Institut Pasteur have developed a method to identify the genomes of different strains in the same environment.